Stock analysts at StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
NASDAQ TTNP opened at $6.35 on Friday. Titan Pharmaceuticals has a 12 month low of $4.24 and a 12 month high of $13.97. The company’s 50-day moving average price is $6.18 and its 200-day moving average price is $6.74.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last issued its earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($1.24) EPS for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Stories
- Five stocks we like better than Titan Pharmaceuticals
- 3 Small Caps With Big Return Potential
- Is This Telehealth Stock a Buy After the Recent Pullback?
- How Investors Can Find the Best Cheap Dividend Stocks
- Safeguard Against Credit Card Risks with This Top Financial Stock
- Why is the Ex-Dividend Date Significant to Investors?
- Streaming Titan’s Stock Ready to Hit All-Time Highs This Year
Receive News & Ratings for Titan Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Titan Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
